Jazz Pharmaceuticals-Jazz (JAZZ) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates

For the quarter ended September 2025, Jazz Pharmaceuticals (JAZZ) reported revenue of $1.13 billion, up 6.7% over the same period last year. EPS came in at$ 8.13, compared to $6.61 in the year-ago quarter.The reported revenue represents a surprise of +2.16% over the Zacks Consensus Estimate of$ 1.1 billion. With the consensus EPS estimate being $5.74, the EPS surprise was +41.64%.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall ...